Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy

Abstract

1. Kim S, Oh J, Chung W et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24: 2899–2908 2. Hoff CM. In vitro biocompatibility performance of physioneal. Kidney Int Suppl 2003; S57–S74 3. Pajek J, Kveder R, Bren A et al. Short-term effects of bicarbonate/ lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant 2009; 24: 1617–1625 4. Glik A, Douvdevani A. T lymphocytes: the ‘cellular’ arm of acquired immunity in the peritoneum. Perit Dial Int 2006; 26: 438–448 5. Saeed AI, Sharov V, White J et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374–378

DOI: 10.1093/ndtplus/sfp134

2 Figures and Tables

Cite this paper

@inproceedings{Kurita2009CrescenticGI, title={Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy}, author={Noriaki Kurita and Naobumi Mise and Akiko Fujii and Shingo Ikeda and Tokuichiro Sugimoto}, booktitle={NDT plus}, year={2009} }